

PCH Medication Standing Orders

Medications listed on standing orders may be used for a maximum of 24 hours. If symptoms persist or the maximum daily dose is reached, contact the prescriber. ■ = Automatically activated. Prescriber: if not in agreement with an order, cross out and initial

	ed, contact the prescriber.			ctivat	ed. Prescr	riber:	if not in agree	ment	with a	n order,	, cross out an	d initial
	R, HEADACHE OR NON-SPE											
	r is defined as: single oral ter	•	•			•	•		_			
temperature greater than 37.5°C OR single temperature greater than a 1.1°C increase over baseline from any site (e.g. oral,												
tympanic, auxiliary). Warning: Total dose of acetaminophen from all sources shall not exceed 4 g in 24 hours. Contact												
prescriber if total dose will exceed 3 g in 24 hours.												
	acetaminophen tablet		325-1000	mg				p	0	Stat + q4h prn or		
	acetaminophen liquid		325-1000 mg			p	0	Stat + q4h prn or				
	acetaminophen supposito	ry				r	ectal	ectal Stat + q4h prn				
MUS	MUSCULOSKELETAL PAIN											
INDI	GESTION/HEARTBURN		,									
	Antacid (Mg 200 mg/5 mL	and Al	hvdroxide 2	200 m	g/5 mL)		15 mL	ро	Stat	+ a2h r	orn (max 4 do	ses)
	*DO NOT USE for resident		-		O/ - /			1		-1 1		,
NAUS	SEA OR VOMITING		u., v					I				
	dimenhyDRINATE tablet		25 mg (1/2 t	ahlet	of 50 mg)				ро		Stat + q4h pri	n or
	dimenhyDRINATE						t in half lengthy	vise)			Stat + q4h prn or	
_	suppository		23 1116 01 30	1116 (-	roo mg sap	рр са	t iii iidii iciigtiiv	viscj	100	-tai	Stat · q+ii pii	11 01
	dimenhyDRINATE injectio	n	25 mg						IM		Stat + q4h pri	n
	RHEA - 3 or more loose bow			ntact i	nroccribor	if cov	oro or parciete	longo		<u> </u>		
DIAN				itact	prescriber	II Sev	ere or persists	longe	ulali	24 HOUI	3.	
	Hold laxatives, cathartics,						****** 24 h a					
	ITING or DIARRHEA – Conta	•							-1 -11			
	rehydration solution (ORS):		-		-		-	-			-	
	mic bowel before ORS. Deter	_					ns (risk of aspir	ation,	CHF, S	evere ai	baominai paii	n,
	nic kidney disease). Contact t	-	-		-							
	sachet in 200 mL of water a											
	PHYLACTIC SHOCK - Call 911											
	EPINEPHrine 1 mg/mL	0.3 m	g (0.3 mL)	IM	Stat an	nd rep	eat at 5-15 mir	nute ir	iterval	s to a m	naximum of 3	doses.
	T PAIN											
	est pain does not resolve or v											
	er than or equal to 90% or t			e. Giv	e ASA and	d info	rm prescriber.	Also i	nform	prescri	ber if new on	set or
unan	ticipated chest pain based o	n resid	ent history.									
	nitroglycerin tablet	0.3 m	g (1 tab)		sublingua	al	Stat and repeat x 2 at 5 minute intervals if required.				ired.	
	acetylsalicylic acid (ASA)	160-1	.62 mg (2 x 8	0	chew		Stat if chest pain is unresponsive to 3 doses of					
		mg or	2 x 81 mg ta	abs)			nitroglycerin.					
RESP	IRATORY DISTRESS											
Call p	rescriber promptly for new	or wor	sening respi	ratory	distress a	and/o	r hypoxemia (O	2 satu	ration	less tha	n 90%). Initia	te O ₂
at 1 L/min via nasal cannulae to a maximum of 5 L/min and titrate to maintain O ₂ sat greater than 90% or their normal baseline.												
	salbutamol inhaler 100 me	cg/dose	e 2 puffs		inhaled		Stat & contact	t preso	criber			
CONS		_		and is	dependen	nt on c	resident's usu	al bov	vel hab	its and	symptoms.	
CONSTIPATION *The number of days is a guideline and is dependent on a resident's usual bowel habits and symptoms. ■ Dietary measures (e.g. prune juice 120 mL po daily prn, fruitlax 25 g po daily prn)												
If no bowel movement on day 2 , perform abdominal assessment												
	•			. 4550		enno	sides 8 6 mg			2 tabs	ро	HS
If no bowel movement on <u>day 3</u> , perform abdominal assessment and rectal check If stool is <u>hard</u> , give the following: glycerin suppository 1 supp rectal Stat												
-						glycerin suppository				1 supp		Stat
						Stat						
If suppository is not effective after 2 hours, contact prescriber. If there is <u>no stool</u> in the rectum, give: polyethylene glycol (PEG) 17 g <u>or</u> lactulose 15-30 mL po Stat												
	If there is no stool in the r	ectum,	, give:	p	olyethyler	ne gly	col (PEG) 17 g	<u>or</u> Iact	ulose 1	L5-30 m	ıL po	Stat

Generic substitutions will be used unless otherwise specified by the prescriber. Note: This document is to be copied as a 2-sided form Approved by SHSS Pharmacy & Therapeutics Committee: June 12, 2024 Approved by SHSS Regional Medical Advisory Council: June 27, 2024



Long Term Care

MILD ALLERGIC REACTION								
	cetirizine		5-10 mg		ро	Sta	at x 1 dose	
COLIG	H SUPPRESSANT							
E								
			L5-30 mg		ро	o q6h prn		
	CERUMEN MANAGEMENT							
Do not administer if there is a history of ear infections, perforations, otologic surgery or if the status of the tympanic membrane								
IS UIIK	Inknown. mineral oil 2-3 drops Instill into affected ear canal Daily at bedtime for 5-7 days. May repeat x 1							
	If softening with mineral oil is not effective for removing cerumen and no contraindications present:							
	A nurse with training may perform ear irrigation. If irrigation is not effective in the removal of the cerumen after 2 attempts, consult prescriber.							
НҮРО	GLYCEMIA							
If resid	dent is unresponsive, call 911. If blood gluce	ose is less than 4 n	nmol/L and resi	dent is respons	sive give:			
	glucose 4 g 5 tablets (20 g of glucose)	Crush and dissol	ve in 30 mL wat	ter (thicken if r	equired)	ро	Stat	
Reche	ck blood glucose in 15 minutes and if still le	ss than 4 mmol/L	and resident is	responsive give	<u>:</u>		_	
	glucose 4 g 4 tablets (16 g of glucose)	Crush and dissol	ve in 30 mL wat	ter (thicken if r	equired)	ро	Stat	
-	rescriber prior to the next scheduled dose or	f diabetes medicat	ions to discuss	any changes to	blood gluce	ose monit	toring	
	r medication.							
	M CREATININE							
	12 months prior to respiratory season for all	ntiviral dosing calc	ulation unless t	there is a serun	n creatinine	from the	last 3	
	ns in the resident's health record or eChart. ENZA OUTBREAK PROPHYLAXIS							
	preak declared <i>and</i> prophylactic use of oselt	amivir is approved	hy DCH Madic	al Director or N	Andical Offic	or of ⊔os	olth and	
	nt is asymptomatic, give prophylaxis (as per		•					
	ever occurs first.	the table below)	101 10 days of a	intil the outbre	ak is acterii	inica to t	, с о ч с г ,	
	CrCl greater than 60 mL/min	oseltamivir		75 mg	00	daily		
	CrCl greater than 30 up to 60 mL/min	oseltamivir			00	daily		
	CrCl 10-30 mL/min	oseltamivir			00	every ot	her day	
	CrCl less than 10 mL/min or dialysis – Cons	sult the Manitoba	Renal Program	or Infectious D	iseases	,		
VACCI	NATIONS – Review resident's immunization					and then	annually	
in Aug	gust to identify eligibility for the vaccinations	s listed below.					-	
	Influenza vaccine	A	- 1	D 51:-:1	ilia Cala al-	. f D -	al.	
	COVID-19 vaccine	As per Manitoba's Immunization Program Eligibility Criteria for Publicly-					-	
	Pneumococcal vaccine	Funded Vaccines and with informed consent from the resident or substitute decision maker.						
	Respiratory syncytial virus (RSV) vaccine	decision maker.						
Prescriber Signature Printed Name and Designation								
			[Date:	MYYYY	Time:	24 HOUR	

Standing orders are reviewed and signed for annually.

Prescriber Signature	Printed Name and Designation		
		Date: L	Time: 24 HOUR
Prescriber Signature	Printed Name and Designation		
		Date: D M M M Y Y Y Y	Time: 24 HOUR